Titre : Virus parainfluenza de type 5

Virus parainfluenza de type 5 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Up-Regulation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Virus parainfluenza de type 5 : Questions médicales les plus fréquentes", "headline": "Virus parainfluenza de type 5 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Virus parainfluenza de type 5 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-18", "dateModified": "2025-03-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Virus parainfluenza de type 5" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Rubulavirus", "url": "https://questionsmedicales.fr/mesh/D019213", "about": { "@type": "MedicalCondition", "name": "Rubulavirus", "code": { "@type": "MedicalCode", "code": "D019213", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B04.820.480.937.600.650.750" } } }, "about": { "@type": "MedicalCondition", "name": "Virus parainfluenza de type 5", "alternateName": "Parainfluenza Virus 5", "code": { "@type": "MedicalCode", "code": "D045402", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Biao He", "url": "https://questionsmedicales.fr/author/Biao%20He", "affiliation": { "@type": "Organization", "name": "Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States of America." } }, { "@type": "Person", "name": "Keisuke Ohta", "url": "https://questionsmedicales.fr/author/Keisuke%20Ohta", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, School of Medicine, Wakayama Medical University, Wakayama, Japan." } }, { "@type": "Person", "name": "Machiko Nishio", "url": "https://questionsmedicales.fr/author/Machiko%20Nishio", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, School of Medicine, Wakayama Medical University, Wakayama, Japan. Electronic address: mnishio@wakayama-med.ac.jp." } }, { "@type": "Person", "name": "Yusuke Matsumoto", "url": "https://questionsmedicales.fr/author/Yusuke%20Matsumoto", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, School of Medicine, Wakayama Medical University, Wakayama, Japan." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "SP1-mediated up-regulation of lncRNA TUG1 underlines an oncogenic property in colorectal cancer.", "datePublished": "2022-05-04", "url": "https://questionsmedicales.fr/article/35508523", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41419-022-04805-w" } }, { "@type": "ScholarlyArticle", "name": "Involvement of Rab11 in osteoblastic differentiation: Its up-regulation during the differentiation and by tensile stress.", "datePublished": "2022-07-19", "url": "https://questionsmedicales.fr/article/35932574", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bbrc.2022.07.061" } }, { "@type": "ScholarlyArticle", "name": "EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA.", "datePublished": "2022-06-27", "url": "https://questionsmedicales.fr/article/35761386", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13018-022-03181-7" } }, { "@type": "ScholarlyArticle", "name": "LncRNA FEZF1-AS1 promotes pulmonary fibrosis via up-regulating EZH2 and targeting miR-200c-3p to regulate the ZEB1 pathway.", "datePublished": "2024-10-30", "url": "https://questionsmedicales.fr/article/39472569", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-74570-7" } }, { "@type": "ScholarlyArticle", "name": "Daidzein attenuated paclitaxel-induced neuropathic pain via the down-regulation of TRPV1/P2Y and up-regulation of Nrf2/HO-1 signaling.", "datePublished": "2023-05-05", "url": "https://questionsmedicales.fr/article/37145202", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10787-023-01225-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Virus", "item": "https://questionsmedicales.fr/mesh/D014780" }, { "@type": "ListItem", "position": 3, "name": "Virus à ARN", "item": "https://questionsmedicales.fr/mesh/D012328" }, { "@type": "ListItem", "position": 4, "name": "Virus à ARN de polarité négative", "item": "https://questionsmedicales.fr/mesh/D000086103" }, { "@type": "ListItem", "position": 5, "name": "Mononegavirales", "item": "https://questionsmedicales.fr/mesh/D018096" }, { "@type": "ListItem", "position": 6, "name": "Paramyxoviridae", "item": "https://questionsmedicales.fr/mesh/D010252" }, { "@type": "ListItem", "position": 7, "name": "Paramyxovirinae", "item": "https://questionsmedicales.fr/mesh/D018098" }, { "@type": "ListItem", "position": 8, "name": "Rubulavirus", "item": "https://questionsmedicales.fr/mesh/D019213" }, { "@type": "ListItem", "position": 9, "name": "Virus parainfluenza de type 5", "item": "https://questionsmedicales.fr/mesh/D045402" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Virus parainfluenza de type 5 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Virus parainfluenza de type 5", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-30", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Virus parainfluenza de type 5", "description": "Comment diagnostique-t-on une infection par le virus parainfluenza 5 ?\nQuels tests sont utilisés pour confirmer le virus parainfluenza 5 ?\nLes symptômes aident-ils au diagnostic du virus parainfluenza 5 ?\nPeut-on diagnostiquer le virus parainfluenza 5 par sérologie ?\nLes radiographies sont-elles utiles pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D045402?mesh_terms=Up-Regulation&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Virus parainfluenza de type 5", "description": "Quels sont les symptômes courants du virus parainfluenza 5 ?\nLe virus parainfluenza 5 cause-t-il des complications respiratoires ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes persistent-ils longtemps ?", "url": "https://questionsmedicales.fr/mesh/D045402?mesh_terms=Up-Regulation&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Virus parainfluenza de type 5", "description": "Comment prévenir l'infection par le virus parainfluenza 5 ?\nLes vaccins protègent-ils contre ce virus ?\nFaut-il éviter les lieux publics en cas d'épidémie ?\nLe port de masque est-il utile ?\nLes enfants doivent-ils être vaccinés contre d'autres virus respiratoires ?", "url": "https://questionsmedicales.fr/mesh/D045402?mesh_terms=Up-Regulation&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Virus parainfluenza de type 5", "description": "Quel est le traitement principal pour le virus parainfluenza 5 ?\nDes antiviraux sont-ils efficaces contre ce virus ?\nQuand faut-il consulter un médecin ?\nLes inhalateurs sont-ils recommandés ?\nLe repos est-il important lors d'une infection ?", "url": "https://questionsmedicales.fr/mesh/D045402?mesh_terms=Up-Regulation&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Virus parainfluenza de type 5", "description": "Quelles sont les complications possibles du virus parainfluenza 5 ?\nLes personnes âgées sont-elles plus à risque de complications ?\nLe virus peut-il aggraver des maladies préexistantes ?\nLes complications sont-elles fréquentes ?\nComment gérer les complications si elles surviennent ?", "url": "https://questionsmedicales.fr/mesh/D045402?mesh_terms=Up-Regulation&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Virus parainfluenza de type 5", "description": "Quels sont les principaux facteurs de risque d'infection ?\nLes maladies respiratoires augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes nourrissons sont-ils plus à risque ?\nLes conditions de vie affectent-elles le risque d'infection ?", "url": "https://questionsmedicales.fr/mesh/D045402?mesh_terms=Up-Regulation&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une infection par le virus parainfluenza 5 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests PCR, cultures virales et des analyses cliniques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer le virus parainfluenza 5 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests PCR et les cultures de prélèvements respiratoires sont les plus courants." } }, { "@type": "Question", "name": "Les symptômes aident-ils au diagnostic du virus parainfluenza 5 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes cliniques comme la toux et la fièvre orientent le diagnostic." } }, { "@type": "Question", "name": "Peut-on diagnostiquer le virus parainfluenza 5 par sérologie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La sérologie n'est pas couramment utilisée pour ce virus, les tests PCR sont préférés." } }, { "@type": "Question", "name": "Les radiographies sont-elles utiles pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les radiographies peuvent montrer des signes d'infection, mais ne confirment pas le virus." } }, { "@type": "Question", "name": "Quels sont les symptômes courants du virus parainfluenza 5 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent toux, fièvre, congestion nasale et difficultés respiratoires." } }, { "@type": "Question", "name": "Le virus parainfluenza 5 cause-t-il des complications respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut entraîner des complications comme la bronchite ou la pneumonie." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants peuvent présenter des symptômes plus graves que les adultes." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez la détresse respiratoire et la fièvre élevée, surtout chez les enfants." } }, { "@type": "Question", "name": "Les symptômes persistent-ils longtemps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent durer de quelques jours à deux semaines selon la gravité." } }, { "@type": "Question", "name": "Comment prévenir l'infection par le virus parainfluenza 5 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Lavez-vous les mains régulièrement et évitez le contact avec des personnes malades." } }, { "@type": "Question", "name": "Les vaccins protègent-ils contre ce virus ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de vaccin spécifique contre le virus parainfluenza 5 actuellement." } }, { "@type": "Question", "name": "Faut-il éviter les lieux publics en cas d'épidémie ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter les lieux bondés peut réduire le risque de transmission du virus." } }, { "@type": "Question", "name": "Le port de masque est-il utile ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, porter un masque peut aider à réduire la propagation des infections respiratoires." } }, { "@type": "Question", "name": "Les enfants doivent-ils être vaccinés contre d'autres virus respiratoires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vaccination contre d'autres virus comme la grippe est recommandée." } }, { "@type": "Question", "name": "Quel est le traitement principal pour le virus parainfluenza 5 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement est symptomatique, incluant des antipyrétiques et des bronchodilatateurs." } }, { "@type": "Question", "name": "Des antiviraux sont-ils efficaces contre ce virus ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antiviraux spécifiques pour le virus parainfluenza 5." } }, { "@type": "Question", "name": "Quand faut-il consulter un médecin ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si les symptômes s'aggravent ou si la respiration devient difficile." } }, { "@type": "Question", "name": "Les inhalateurs sont-ils recommandés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les inhalateurs peuvent aider à soulager la respiration en cas de bronchospasme." } }, { "@type": "Question", "name": "Le repos est-il important lors d'une infection ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le repos aide le corps à combattre l'infection et à récupérer plus rapidement." } }, { "@type": "Question", "name": "Quelles sont les complications possibles du virus parainfluenza 5 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la bronchite, la pneumonie et des infections secondaires." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque de complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées et immunodéprimées sont plus susceptibles de développer des complications." } }, { "@type": "Question", "name": "Le virus peut-il aggraver des maladies préexistantes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut aggraver des maladies respiratoires chroniques comme l'asthme." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont rares mais peuvent survenir, surtout chez les jeunes enfants." } }, { "@type": "Question", "name": "Comment gérer les complications si elles surviennent ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent souvent une hospitalisation et un traitement médical intensif." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les jeunes enfants, les personnes âgées et celles avec un système immunitaire affaibli sont à risque." } }, { "@type": "Question", "name": "Les maladies respiratoires augmentent-elles le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes ayant des antécédents de maladies respiratoires sont plus vulnérables." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque d'infections respiratoires, y compris parainfluenza." } }, { "@type": "Question", "name": "Les nourrissons sont-ils plus à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les nourrissons ont un système immunitaire immature, les rendant plus vulnérables." } }, { "@type": "Question", "name": "Les conditions de vie affectent-elles le risque d'infection ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, vivre dans des environnements surpeuplés ou insalubres augmente le risque d'infection." } } ] } ] }

Sources (10000 au total)

Involvement of Rab11 in osteoblastic differentiation: Its up-regulation during the differentiation and by tensile stress.

Rab GTPases, the largest group of small monomeric GTPases, have been shown to participate in membrane trafficking involving many cellular processes. However, their roles during osteoblastic differenti...

EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA.

As a skeletal malignancy, osteosarcoma has high incidence among primary malignant bone tumors. With increasing researches on molecules which mediate cancer progression, molecular mechanism has gradual... Our study aimed at investigating the function of G3BP stress granule assembly factor 2 (G3BP2), which is an oncogene for breast cancer (BC) and prostate cancer but remains unknown in osteosarcoma cell... Related gene expression was confirmed by RT-qPCR. Functional assays including immunofluorescence (IF), colony formation, transferase-mediated dUTP nick-end labeling (TUNEL) as well as transwell assays... G3BP2 was with high expression in osteosarcoma cells, and it aggravated the malignant cell behaviors in osteosarcoma. Additionally, miR-124-3p was verified to negatively regulate G3BP2 expression in o... EBF1 induced-FGA5-AS1 aggravated osteosarcoma cell malignancy by targeting miR-124-3p and G3BP2....

LncRNA FEZF1-AS1 promotes pulmonary fibrosis via up-regulating EZH2 and targeting miR-200c-3p to regulate the ZEB1 pathway.

The role and detailed mechanisms of lncRNAs in idiopathic pulmonary fibrosis (IPF) are not fully understood. qPCR was conducted to verify lncRNA FEZF1-AS1 expression in the transforming growth factor-...

SOX21-AS1 activated by STAT6 promotes pancreatic cancer progression via up-regulation of SOX21.

Pancreatic cancer (PC) is a highly malignant tumor which threatens human's health. Long non-coding RNAs (lncRNAs) are implicated in many cancers, including PC, but their mechanisms in PC have not yet ... Functional assays assessed SOX21-AS1 function on PC progression. Bioinformatics analysis, along with mechanism assays were taken to unmask the regulatory mechanism SOX21-AS1 may exert in PC cells.... SOX21-AS1 possessed a high expression level in PC cells. SOX21-AS1 absence suppressed PC cell proliferation, migration, stemness and epithelial-mesenchymal transition (EMT) while elevated cell apoptos... SOX21-AS1 aggravated the malignant development of PC, which might provide the utility value for PC treatment....

Up-regulation of matrix metalloproteinase-9 in primary bone tumors and its association with tumor aggressiveness.

Understanding the molecular mechanism underlying the pathophysiology of primary skeletal tumors is crucial due to the tumor-related complications, incidence at a young age, and tumor recurrence.... The local expression pattern of MMP-9 as an active matrix-degrading protease was detected in 180 bone tissues, including 90 tumors and 90 noncancerous tissues, utilizing real-time qRT-PCR at the mRNA ... The data propose that MMP-9 may be involved in the proliferation and invasion of primary bone tumors and has the potential to monitor and treat the progression of malignant tumors....